Vivesto Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 5

Employees

  • Stock Symbol
  • VIVE

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.71
  • (As of Monday Closing)

Vivesto General Information

Description

Vivesto AB is a Swedish drug development company developing treatment options for difficult-to-treat cancers with high medical need and market potential. The company focuses on hematological cancers, particularly acute myeloid leukemia (AML). Its project portfolio consists of Cantrixil, which is being evaluated in the preclinical phase for refractory human AML, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a clinical pilot study in dogs with splenic hemangiosarcoma (HSA) following splenectomy and in a dose-finding study in cats with solid tumors.

Contact Information

Website
www.vivesto.com
Formerly Known As
Oasmia Pharmaceutical AB, Oasmia Pharmaceutical
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Gustav III:s Boulevard 46
  • 5th floor
  • 169 73 Solna
  • Sweden
+46
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Commercial Services
Stock Exchange
STO
Vertical(s)
Corporate Office
  • Gustav III:s Boulevard 46
  • 5th floor
  • 169 73 Solna
  • Sweden
+46

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vivesto Stock Performance

As of 16-Nov-2026, Vivesto’s stock price is $0.71. Its current market cap is $7.87M with 11.1M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.71 $0.72 $0.65 - $2.20 $7.87M 11.1M 8.19K -$0.44

Vivesto Financials Summary

As of 30-Jun-2026, Vivesto has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 6,445 7,748 10,462 14,158
Revenue 0 0 0 0
EBITDA (3,281) (3,260) (3,457) (11,647)
Net Income (3,369) (3,469) (3,759) (12,112)
Total Assets 17,347 16,197 15,669 22,081
Total Debt 0 1,413 134 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vivesto Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vivesto‘s full profile, request access.

Request a free trial

Vivesto Patents

Vivesto Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026130838-A1 The combination of trx-e-002-1 with a bcl-2 inhibitor or a hypomethylating agent in the treatment of acute myeloid leukemia Pending 17-Dec-2024
WO-2026013253-A1 Process for the preparation of n-retinoyl-l-cysteic acid methyl esters Pending 11-Jul-2024
AU-2023353939-A1 Solubilizing compounds Pending 26-Sep-2022
EP-4593959-A1 Solubilizing compounds Pending 26-Sep-2022
US-20260337156-A1 Solubilizing compounds Pending 26-Sep-2022 C07C309/51
To view Vivesto’s complete patent history, request access »

Vivesto Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vivesto Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vivesto‘s full profile, request access.

Request a free trial

Vivesto Investments (2)

Vivesto’s most recent deal was a Corporate Asset Purchase with Kazia Therapeutics (Cantrixil) for . The deal was made on 29-Mar-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Kazia Therapeutics (Cantrixil) 29-Mar-2021 Corporate Asset Purchase Buildings and Property
Karo Pharma (Cancer Project KB9520) 24-Oct-2016 Corporate Asset Purchase Buildings and Property
To view Vivesto’s complete investments history, request access »

Vivesto ESG

Risk Overview

Risk Rating

Updated October, 31, 2023

25.61 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,766

Rank

Percentile

Pharmaceuticals

Industry

of 891

Rank

Percentile

Biotechnology

Subindustry

of 394

Rank

Percentile

To view Vivesto’s complete esg history, request access »

Vivesto FAQs

  • When was Vivesto founded?

    Vivesto was founded in 1999.

  • Where is Vivesto headquartered?

    Vivesto is headquartered in Solna, Sweden.

  • What is the size of Vivesto?

    Vivesto has 5 total employees.

  • What industry is Vivesto in?

    Vivesto’s primary industry is Drug Discovery.

  • Is Vivesto a private or public company?

    Vivesto is a Public company.

  • What is Vivesto’s stock symbol?

    The ticker symbol for Vivesto is VIVE.

  • What is the current stock price of Vivesto?

    As of 16-Nov-2026 the stock price of Vivesto is $0.71.

  • What is the current market cap of Vivesto?

    The current market capitalization of Vivesto is $7.87M.

  • What is Vivesto’s annual earnings per share (EPS)?

    Vivesto’s EPS for 12 months was -$0.44.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process